Indaptus Therapeutics (INDP) vs Ovid Therapeutics (OVID)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ovid Therapeutics (OVID) has outperformed Indaptus Therapeutics (INDP) over the past year, gaining 57.1% versus a gain of 52.4%. Over five years, OVID leads with a -32.5% price change compared with -98.3% for INDP. Indaptus Therapeutics is the larger company by market cap ($433.2 million vs $415.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INDP | OVID |
|---|---|---|
| Share price | $2.82 | $2.20 |
| Market cap | $433.16M | $415.21M |
| 1-day change | -9.90% | -5.98% |
| YTD return | -3.09% | +34.97% |
| 1-year return | +52.43% | +57.14% |
| 5-year return | -98.26% | -32.52% |
| EPS (TTM) | $-3.16 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $7.25M |
| Revenue growth (YoY) | — | +1181.27% |
| Net income (latest FY) | $-20.85M | $-17.41M |
| Operating margin | — | -585.20% |
| Net margin | — | -240.13% |
| 52-week high | $5.96 | $3.11 |
| 52-week low | $0.92 | $1.26 |
| Distance from 52-week high | -52.68% | -29.15% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +179.55% |
| Average volume | 712.87K | 1.98M |
| Shares outstanding | 153.60M | 188.73M |
| Employees | 5 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Indaptus Therapeutics
INDP stock →Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Ovid Therapeutics
OVID stock →Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
INDP vs OVID FAQ
Which is bigger, Indaptus Therapeutics or Ovid Therapeutics?
Indaptus Therapeutics (INDP) is larger, with a market capitalization of $433.16M compared with $415.21M for Ovid Therapeutics (OVID).
Which stock has performed better over the past year, INDP or OVID?
OVID returned +57.14% over the past 12 months, compared with +52.43% for INDP (price return, excluding dividends). Past performance does not predict future results.
Are Indaptus Therapeutics and Ovid Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.